Market Exclusive

INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Submission of Matters to a Vote of Security Holders

INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

Submission of Matters to a Vote of Security
Holders

Intellia Therapeutics, Inc. (the Company) held its Annual Meeting
of Stockholders on May18, 2017. The following is a summary of the
matters voted on at that meeting.

a) The stockholders of the Company elected Nessan Bermingham,
Ph.D. and Jean-Franois Formela, M.D. as class I directors,
each for a three-year term ending at the annual meeting of
stockholders to be held in 2020 and until his successor has
been duly elected and qualified or until his earlier
resignation or removal. The results of the stockholders vote
with respect to the election of the class I directors were as
follows:

Name

VotesFor Votes Withheld BrokerNon-Votes

Nessan Bermingham, Ph.D.

27,949,155 262,647 3,606,751

Jean-Franois Formela, M.D.

27,621,404 590,398 3,606,751
b) The stockholders of the Company ratified the selection of
Deloitte Touche LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017. The results of the stockholders vote with respect to
such ratification were as follows:
For Against Abstain
31,729,132 56,342 33,079
c) The stockholders of the Company ratified the Companys Amended
and Restated 2015 Stock Option and Incentive Plan. The
results of the stockholders vote with respect to such
ratification were as follows:
For Against Abstain BrokerNon-Votes
27,501,943 700,154 9,705 3,606,751

About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue. INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Recent Trading Information
INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) closed its last trading session up +0.45 at 14.35 with 177,634 shares trading hands.

Exit mobile version